Hepatitis B & C & Regenerative Medicine
- Written by
- StemCell Longevita Editorial Team
- Medically reviewed by
- Prof. Dr. Erdal Karaöz TeamProfessor of Histology and Embryology · Medical Director, Center for Regenerative Medicine
- Last reviewed
- Next scheduled review
How we evaluate evidence · Conflict-of-interest disclosure · Editorial standards
Advanced regenerative treatment for hepatitis-related liver damage. Support your liver's natural healing with cutting-edge stem cell technology.
Can stem cell therapy help chronic hepatitis?
Mesenchymal stem cell therapy is not an approved treatment for viral or autoimmune hepatitis. Modern antiviral therapy achieves virological cure in most patients with hepatitis C and long-term suppression in hepatitis B; autoimmune hepatitis responds to established immunosuppression. Small MSC studies in decompensated liver disease report short-term safety but no consistent outcome benefit. Cause-directed care remains the evidence-based mainstay.
Key facts
- Approval status
- Not approved for hepatitis
- HCV standard care
- Direct-acting antivirals — high cure rates
- AIH standard care
- Established immunosuppression
What we know
- Direct-acting antivirals cure most hepatitis C infection and are widely available.
What remains uncertain
- Whether MSC administration alters clinical outcomes when standard therapy is already achieving virological control.
Medically reviewed questions
This summary is general medical information, not medical advice, and not a promise of benefit. Figures are quoted ranges, confirmed in writing after a medical review.
Medically reviewed by: Prof. Dr. Erdal Karaöz · Last updated: · Editorial and evidence policy
Evidence at a glance — Chronic hepatitis-related liver injury
A plain summary of what the published research does and does not show for this condition. It is written to the same standard whether the evidence is strong or weak.
- Human studies available?
- Yes — early-stage only
- Randomised trials?
- Few randomised trials; overlaps with cirrhosis evidence
- Main outcomes studied
- Liver enzymes
- Fibrosis markers
- MELD score
- Safety
- Long-term evidence
- Very limited
- Regulatory approval for this indication
- United States (FDA): No FDA-approved mesenchymal stem cell product for this indication. The FDA has issued consumer warnings about unapproved stem cell products.
- European Union (EMA): No EMA-authorised mesenchymal stem cell medicine for this indication.
- United Kingdom (MHRA): No MHRA-authorised mesenchymal stem cell medicine for this indication.
- Türkiye (Ministry of Health): In Türkiye, cell therapies are delivered only inside Ministry of Health–licensed centres under the regenerative medicine / advanced therapy regulations, as clinical research or individual (exceptional) use — not as an approved routine treatment for this indication.
- Role at our centre
- Research context — considered only where standard care is exhausted or unsuitable, and never as a replacement for it
What kind of evidence exists
- Mechanism (laboratory): Documented
- Animal / preclinical: Documented
- Early human (phase 1/2, uncontrolled): Documented
- Controlled human (randomised or sham-controlled): Documented
- Regulatory approval: Not established
Sources
- Systematic reviews and meta-analyses — Chronic hepatitis-related liver injury — PubMed
- Randomised controlled trials — Chronic hepatitis-related liver injury — PubMed
- Registered MSC trials — Chronic hepatitis-related liver injury — ClinicalTrials.gov
- FDA — Consumer alert on regenerative medicine therapies — U.S. Food and Drug Administration, 2024
- Advanced therapy medicinal products: overview — European Medicines Agency, 2025
- ISSCR Guidelines for Stem Cell Research and Clinical Translation — International Society for Stem Cell Research, 2021
- ISSCR Patient Handbook on Stem Cell Therapies — International Society for Stem Cell Research, 2020
Source links open filtered searches of PubMed and ClinicalTrials.gov plus regulator and professional-society pages, so you can read the current evidence yourself rather than a selected extract.
This summary is general information about the evidence base, not medical advice and not a promise of benefit. Whether any treatment is appropriate for you can only be decided after a medical review of your records.
What Is Regenerative Approach for Hepatitis?
Hepatitis B and C are viral infections that cause chronic inflammation of the liver. Over time, this ongoing inflammation can lead to progressive liver damage, including fibrosis, cirrhosis, and impaired liver function. While antiviral medications can control or eliminate the virus, they cannot support recovery from existing liver damage.
Regenerative medicine approach offers a regenerative approach to hepatitis-related liver disease. Mesenchymal stem cells (MSCs) derived from umbilical cord tissue possess remarkable anti-inflammatory and regenerative properties. When administered, these cells migrate to damaged liver tissue where they promote hepatocyte regeneration, reduce fibrosis, and support overall liver function recovery.
At StemCell Longevita, we combine regenerative medicine approach with comprehensive hepatology care to provide patients with the optimal support for their liver health journey.
Important Note
Regenerative medicine approach for hepatitis works best when combined with appropriate antiviral medication. Our team coordinates care with your hepatologist for optimal results.
Benefits of Regenerative Approach for Hepatitis
Discover how regenerative medicine can support liver health and recovery from hepatitis-related damage.
Liver Regeneration
Stem cells promote hepatocyte regeneration and repair damaged liver tissue at the cellular level.
Anti-Fibrotic Effects
MSCs can help support liver recovery from fibrosis by reducing collagen deposits and scar tissue formation.
Immune Modulation
Regulates immune response to reduce inflammation and prevent further autoimmune damage to the liver.
Improved Liver Function
Enhances overall hepatic function including protein synthesis, detoxification, and bile production.
Reduced Inflammation
Anti-inflammatory properties of stem cells help calm chronic hepatic inflammation.
Long-Term Recovery
Supports sustained improvement with progressive healing over months following treatment.
How Stem Cells Work for Hepatitis
Regenerative medicine approach for hepatitis focuses on repairing liver tissue damaged by chronic viral infection. Mesenchymal stem cells (MSCs) possess unique hepatotropic properties, meaning they naturally migrate toward injured liver tissue where they promote hepatocyte regeneration, reduce fibrotic scarring, and modulate the immune response that perpetuates liver damage.
MSCs differentiate into hepatocyte-like cells and secrete hepatocyte growth factor (HGF), which clinical studies suggest promotes the regeneration of functional liver tissue. This process helps restore the liver's capacity for detoxification and protein synthesis.
Stem cells release anti-fibrotic cytokines including matrix metalloproteinases (MMPs) that break down excess collagen deposits. Research indicates this mechanism may help support recovery from early-stage liver fibrosis caused by chronic hepatitis infection.
MSCs modulate the immune system by suppressing overactive T-cell responses and reducing pro-inflammatory cytokines such as TNF-alpha and IL-6. This helps calm the chronic inflammation that drives ongoing liver damage in hepatitis patients.
Stem cells promote angiogenesis and restore microvascular architecture within damaged liver tissue. Clinical observations suggest this improved blood flow enhances nutrient delivery and supports the survival of newly regenerated hepatocytes.
Who Is a Good Candidate?
Regenerative medicine approach for hepatitis is most effective for patients with chronic liver damage who are seeking to complement their existing antiviral medication with regenerative support.
Ideal Candidates
- Patients with chronic hepatitis B or C who have developed liver fibrosis (stages F1-F3) despite antiviral medication
- Individuals with persistently elevated liver enzymes indicating ongoing hepatic inflammation
- Patients who have achieved viral suppression but still experience residual liver dysfunction
- Those with early-stage cirrhosis (Child-Pugh A) seeking to prevent disease progression
- Patients with post-hepatitis liver damage who want to support natural tissue repair and regeneration
May Not Be Suitable
- Patients with decompensated cirrhosis (Child-Pugh C) or active liver failure requiring transplant evaluation
- Individuals with active, untreated hepatitis infection without concurrent antiviral therapy
- Patients with hepatocellular carcinoma or other active liver malignancies
- Those with severe portal hypertension or uncontrolled variceal bleeding
What Results Can You Expect?
Recovery from regenerative medicine approach for hepatitis follows a gradual trajectory as liver tissue regenerates. Results vary depending on the degree of existing liver damage, viral status, and overall health.
Initial Recovery
Patients typically experience mild fatigue as the body responds to treatment. Stem cells begin migrating to damaged liver tissue and initiating anti-inflammatory processes.
Early Improvements
Clinical studies suggest liver enzyme levels (ALT, AST) may begin to normalize. Patients often report improved energy levels and reduced symptoms of hepatic fatigue.
Progressive Results
Liver function parameters typically show measurable improvement. FibroScan scores may begin to decrease as fibrotic tissue is gradually remodeled by stem cell activity.
Optimal Results
Significant improvements in liver function tests and imaging studies are commonly observed. Many patients report substantially improved quality of life and digestive function.
Long-Term Benefits
Continued liver regeneration and fibrosis reduction may be observed on follow-up imaging. Sustained improvements in liver synthetic function and overall hepatic health are typical.
Individual results vary. These timelines are based on clinical observations and are not guaranteed outcomes. Your specialist will provide personalized expectations during your consultation.
Patient Experiences
Real outcomes from patients who chose regenerative medicine at StemCell Longevita Istanbul
"My hepatologist said the liver scan improvement was remarkable. I was preparing for the worst — now I'm planning for the future."
"I flew to Istanbul sceptical. Six months later, my endocrinologist at home took me off insulin. The numbers speak for themselves."
Hepatitis & Liver Conditions Treated
Our stem cell protocols address various hepatitis-related liver conditions and complications.
Hepatitis B
Chronic HBV infection affecting liver function. Stem cells help reduce viral load impact and support liver regeneration.
Hepatitis C
Persistent HCV infection causing liver inflammation. MSC therapy promotes tissue repair and immune modulation.
Liver Fibrosis
Scarring of liver tissue from chronic hepatitis. Stem cells can help support recovery from early-stage fibrosis and prevent progression.
Liver Cirrhosis
Advanced liver damage from prolonged infection. Regenerative therapy supports remaining healthy tissue and improves function.
Post-Hepatitis Liver Damage
Residual damage after viral clearance. Stem cells are studied for their effect on tissue repair and liver function.
Hepatic Insufficiency
Reduced liver function due to chronic disease. MSC therapy helps optimize remaining liver function.
Your approach Journey
Our comprehensive approach ensures you receive personalized care at every step, from initial evaluation through long-term follow-up.
Comprehensive Liver Assessment
Complete hepatic panel, viral load testing, FibroScan, and imaging studies to evaluate liver health.
Medical Consultation
In-depth review with our hepatology specialists to discuss your condition and treatment options.
Customized Protocol Design
Personalized regenerative medicine approach plan based on disease stage, liver function, and health goals.
Stem Cell Administration
IV infusion of high-quality mesenchymal stem cells in our state-of-the-art facility.
Post-Treatment Monitoring
Regular follow-up with liver function tests and imaging to track regeneration progress.
Same-Day Discharge
Most patients return home the same day
Frequently Asked Questions
Get answers to common questions about regenerative medicine approach for hepatitis and liver conditions.
Watch Our Patient Stories & Expert Insights
See real results and hear from our medical team about stem cell therapy treatments, procedures, and patient outcomes.
All Regenerative Medicine Applications
Explore our comprehensive range of regenerative medicine applications for various conditions. Click any option to learn more.
Related Treatments
Cardiovascular Disease
Learn about candidacy, delivery, evidence, and follow-up for Cardiovascular Disease.
Learn MoreAngina
Learn about candidacy, delivery, evidence, and follow-up for Angina.
Learn MoreIschemic Cardiomyopathy
Learn about candidacy, delivery, evidence, and follow-up for Ischemic Cardiomyopathy.
Learn MoreRelated Articles
Explore our in-depth research articles and guides on related treatments and therapies.
Regenerative Medicine for Liver Disease: Support & Progress
How mesenchymal stem cell approaches may support liver health in cases of cirrhosis, fatty liver, and fibrosis, promoting tissue support and hepatic function.
Read ArticleManaging Diabetes with Regenerative Medicine
Explore the role of regenerative medicine in diabetes management, including potential benefits for insulin production and blood sugar regulation through cellular regeneration.
Read ArticleUnderstanding Regenerative Medicine: A Complete Guide
A comprehensive overview of stem cell therapy, including types of stem cells, care processes, safety considerations, and what patients can expect during their wellness journey.
Read ArticleHow Much Does This Cost Worldwide?
Compare this regenerative medicine costs at StemCell Longevita versus clinics in other countries.
| Country | Typical Cost |
|---|---|
| United States | $15,000 – $30,000 |
| United Kingdom | £12,000 – £25,000 |
| Germany | €15,000 – €30,000 |
| South Korea | $12,000 – $25,000 |
| StemCell Longevita (Turkey) | From £7,600 |
Prices based on market research of comparable stem cell clinics offering umbilical cord-derived MSC treatments (2025-2026). Actual prices vary by clinic, cell count, and condition.
Related clinical questions
Where this page sits in the wider picture.